GOLDENWELL BIOTECH INC.

As of June 30, 2026, GOLDENWELL BIOTECH INC. carries a market capitalization of 51.48M, placing it among publicly traded companies globally. Its enterprise value stands at 51.61M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, GOLDENWELL BIOTECH INC. has 99.00M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 929,933.33, and the price-to-book ratio stands at -129.28.

These figures are as of June 30, 2026. The EV/Sales ratio of 938,353.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 51.61M versus a market cap of 51.48M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, GOLDENWELL BIOTECH INC. maintains a current ratio of 0.29, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -35.31, indicating conservative leverage, while an interest coverage ratio of -13.67 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -201.32, reflecting losses generated across the asset base. The company generates approximately 18.33 in revenue per employee across its workforce of 3.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.00 indicates how many times GOLDENWELL BIOTECH INC. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 20, 2026, GOLDENWELL BIOTECH INC.'s stock has gained approximately 225.00% over the past 52 weeks.

Over the twelve months ended June 30, 2026, GOLDENWELL BIOTECH INC. generated 55.00 in revenue and converted that into -282,117.00 in net income, yielding earnings per share of 0.00. EBITDA reached -114,801.00, while operating income came in at -114,801.00.

As of June 30, 2026, GOLDENWELL BIOTECH INC. holds 11,143.00 in cash and equivalents against 140,588.00 in total debt, resulting in a net debt position of 129,445.00. Total book value stands at -398,194.00, with working capital of -71,022.00 providing operational flexibility.

GOLDENWELL BIOTECH INC. produced -110,365.00 in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, GOLDENWELL BIOTECH INC. posted a gross margin of 21.82, reflecting its pricing power and cost economics. The operating margin of -208,729.09 and net profit margin of -512,940.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.22: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.09, meaning GOLDENWELL BIOTECH INC. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, GOLDENWELL BIOTECH INC. has an Altman Z-Score of -26.35, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.